A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
Terminated · Phase 3 · NCT04044690
Conditions: Dermatomyositis
At a glance
- Research payments reported, 2025
- $239,589
- U.S. investigators named
- 14
- Sites paid
- 14
- Planned or actual enrollment
- 134
About the trial
- Sponsor
- CSL Behring
- Tested
- human immunoglobulin G (drug), Placebo (drug)
- Dates
- Started 2019-10-21; completion 2024-12-02
- Results posted
- Yes
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in comparison to placebo in adult subjects with DM, as measured by responder status based on Total Improvement Score (TIS) assessments.
From ClinicalTrials.gov, last updated 2025-12-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $239,589 in research payments for this study in 2025 (102 payments).
Products named: Hizentra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mona S. Amin, D.O. Rheumatology · Glendale, AZ
- Kumaraswamy Sivakumar, M.D. Physical Medicine & Rehabilitation (PM&R) · Phoenix, AZ
- Christina M. Charles-schoeman, MD Rheumatology · Los Angeles, CA
- Kwabena Ayesu, MD Internal Medicine · Orlando, FL
- Juan Jose Maya Villamizar, M.D. Rheumatology · Lake Worth, FL
- Tuan H. Vu, MD Neurology · Tampa, FL
- Mamatha Pasnoor, MD Neurology · Kansas City, KS
- Jisna R. Paul, MD Rheumatology · Hilliard, OH
- Nizar Chahin, M.D. Neurology · Portland, OR
- Siamak Moghadam-kia, M.D., M.P.H. Rheumatology · Pittsburgh, PA
- Victoria P. Werth, MD Dermatology · Philadelphia, PA
- Jacob Aelion, M.D. Specialist · Jackson, TN
- Tulio Bertorini, MD Neurology · Memphis, TN
- Suur Biliciler, MD Physical Medicine & Rehabilitation (PM&R) · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Neuromuscular Research Center $38,411
- The Ohio State University C/o Wexner Medical Center $37,743
- Hospital of Univ of Pennsylvania, PA $32,621
- University of South Florida $19,721
- Ohsu Hospital and Clinics, OR $18,438
- Ronald Reagan UCLA Medical Center, CA $16,034
- West Tennessee Research Institute $15,411
- Omega Research Maitland, Llc $14,759
- Kumc Research Institute, Inc. $13,659
- Reciomed Clinical Research Network $12,250
- Arizona Arthritis and Rheaumatology Research $8,501
- The University of Texas Health Science Center at Houston $8,132
- Interspond, Llc $2,114
- UPMC Hillman Cancer Center $1,795
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.